Mesoblast Ltd

LWB1

Company Profile

  • Business description

    Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

  • Contact

    55 Collins Street
    Level 38
    MelbourneVIC3000
    AUS

    T: +61 396396036

    E: [email protected]

    https://www.mesoblast.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    73

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,924.2245.760.58%
DAX 4024,569.7820.220.08%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,968.73101.711.15%
HKSE24,028.37136.050.57%
NASDAQ20,611.34192.870.94%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers